Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease | Zendy

Dhruv S. Kazi | Zendy; Andrew E. Moran | Zendy; Pamela G. Coxson | Zendy; Joanne Penko | Zendy; Daniel A. Ollendorf | Zendy; Steven D. Pearson | Zendy; Jeffrey A. Tice | Zendy; David Guzman | Zendy; Kirsten BibbinsDomingo | Zendy

Open Access

Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease

Author(s) -

Dhruv S. Kazi,

Andrew E. Moran,

Pamela G. Coxson,

Joanne Penko,

Daniel A. Ollendorf,

Steven D. Pearson,

Jeffrey A. Tice,

David Guzman,

Kirsten BibbinsDomingo

Publication year - 2016

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2016.11004

Subject(s) - medicine , familial hypercholesterolemia , pcsk9 , atherosclerotic cardiovascular disease , disease , ldl cholesterol , ldl receptor , cholesterol , lipoprotein

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors were recently approved for lowering low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD) and have potential for broad ASCVD prevention. Their long-term cost-effectiveness and effect on total health care spending are uncertain.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research